Ibrutinib May Boost Efficacy of CAR T Cells.
Preliminary results from two studies indicate that concurrent treatment with ibrutinib may boost CAR T-cell therapy response rates among patients with relapsed/refractory CLL, while also minimizing the risk of severe cytokine release syndrome.